| Literature DB >> 35269690 |
Marta Himelreich-Perić1,2, Ana Katušić-Bojanac1,2, Marko Hohšteter3, Nino Sinčić1,2, Vedrana Mužić-Radović4, Davor Ježek1,5.
Abstract
Mast cells (MCs) are an evolutionary well-conserved type of cells, mediating and modulating allergic responses in innate immunity and tissue remodeling after chronic inflammation. Among other tissues, they inhabit both the testis and epididymis. In the testis, MCs usually appear in the interstitial compartment in humans, but not in other standard experimental models, like rats and mice. MCs seem to be responsible for testicular tissue fibrosis in different causes of infertility. Although experimental animal models follow the effect on MC activation or penetration to the interstitial tissue like in humans to some extent, there is an inconsistency in the available literature regarding experimental design, animal strain, and detection methods used. This comprehensive review offers an insight into the literature on MCs in mammalian testes and epididymides. We aimed to find the most suitable model for research on MC and offer recommendations for future experimental designs. When using in vivo animal models, tunica albuginea incorporation and standard histological assessment need to be included. Domesticated boar strains kept in modified controlled conditions exhibit the highest similarity to the MC distribution in the human testis. 3D testicular models are promising but need further fine-tuning to become a valid model for MC investigation.Entities:
Keywords: epididymis; mammal; mast cells; model; testis
Mesh:
Year: 2022 PMID: 35269690 PMCID: PMC8909951 DOI: 10.3390/ijms23052547
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Mast cell (MC) biology and pathophysiology. (1) The CD34+ hematopoietic stem cell is the MC precursor differentiating into MC progenitors in the bone marrow. They reach the tissues MCs reside in and differentiate locally. (2) Under various stimuli, MCs degranulate, and the secreted mediators affect surrounding cells. (3) MCs are crucial in the pathophysiology of asthma, gastrointestinal disorders, allergy, cardiovascular disease, vasodilatation, hematostasis, and cancer. (4) MCs can be activated by immunoglobulin (Ig)E-dependent and IgE-independent pathways. IgE-dependent stimulation starts with pre-exposure to an antigen, which sensitizes the MC. The second exposure links the IgE and high-affinity IgE receptor (FcεR1) with the antigen and causes degranulation. The IgE-independent pathway does not require sensitization. Various mediators (neuropeptide Y, substance P, complement fragments polypeptides, cytokines, toxins) can directly activate or degranulate MCs.
Figure 2MCs in the (A) regular and (B) pathologically affected testis. The testis typically contains MCs that have a role in vascular permeabilization, testicular immune privilege, and immunomodulation. If the testis is affected by infection, inflammation, environmental factors, tumors, cryptorchidism, or testicular torsion, MCs increase in number or degranulate and may lead to the severity of the fibrosis, even germ cell loss and tubular wall thickening. SC—Sertoli cell, GC—germ cell, LC—Leydig cell, MP—macrophage.
Figure 3Representative images of rat testis (A) and epididymis (B), stained with an antibody against mast cell (MC) tryptase. Unlike the rat, human testicular interstitium (C) typically contains MCs; (D) human epididymis. DAB stain, hematoxylin counterstain, scale bar 25 µm.
Experiments on animal models analyzing mast cells in the testis.
| Animal | Strain | Experiment | Analysis | Result—MC | Result—ST | Result—Interstitium | Fertility * | Ref. |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
|
| Wistar | EDS daily PND 5–16 | PND 6–108 | MC in interstitium at PND 17–35 and increased number of MCs under the TA PND 17–108 | valuolae in SCs, thick basal lamina from PND 11; atrophic ST with no GCs or lumen from PND 28; no recovery after treatment | no LC from PND 11 | NA | [ |
| Sprague-Dawley | EDS single dose | 0–49 days after treatment | MCs in interstitium, max. 21 days after EDS | ST volume decrease: lowest 14 days after treatment; control levels 35 days after treatment | no LC on day 3 after EDS, recovered 50% by day 28 after EDS | NA | [ | |
| Sprague-Dawley | 1. EDS treatment ± testosterone implant | 3–10 weeks after treatment | 1. MCs in interstitium 21 and 70 days after EDS treatment | 1. 3–4× increased GC degeneration | 1. LC depletion | 1. transient subfertility in 50% | [ | |
| Sprague-Dawley | EDS ± | 3–41 days after treatment | MC increase in interstitium 21–41 days post-treatment (EDS); slower increase with testosterone | NA | LC depletion, initial macrophage increase (3–10 days), then depletion, prevented by testosterone | NA | [ | |
| Wistar | 1. hypophysectomy ± EDS (adult) OR GnRH antagonist (prepubertal); colchicine | 1–30 days after treatment | 1. MC proliferation on day 20 by EDS, MC number increase 15–30 day (control) and 15–50 day in hypophysectomiy + EDS | NA | 1. mitosis-3rd and 18–22nd day | NA | [ | |
| Sprague Dawley | cyclophosphamide ± | after 4 weeks of treatment | MC number increase in interstitium; ZnO NP reduced (near normal MC number) | ZnO NP reduced ST and GC atrophy, separation of germinal epithelium from BM, tubular wall vacuolization, sperm abnormalities | wide interstitium, vascular congestion, acidophilic material, clusters of dark LC; ZnO NP reduced | NA | [ | |
|
| NMRI | cyclophosphamide ± | after treatment | MC number increase in interstitium; EP reduced | germinal epithelium disarrangement and thickening; EP reduces | LC depletion; EP reduced | NA | [ |
|
| ||||||||
|
| Wistar and Sprague-Dawley | EAO (3 injections every 15 days) | 7–80 days after 1st injection | MC degranulation, number elevation after 80 days, 2× Sprague-Dawley and 5× Wistar | aspermatogenesis at day 80 | mononuclear cell infiltrate at day 80 | NA | [ |
| Wistar | EAO | 50 & 80 days after EAO | MC number and degranulation increase; MC in interstitium | almost complete loss of GC | granuloma formation; PAR2+ cell number increase | NA | [ | |
| Wistar | testis puncture Ø 3 mm (=EAO) followed by skin suture ± | 1–30 days after treatment | ketotifen reduced MC number and degranulation increase in interstitium | GC depletion and ST fibrosis; ketotifen (does not prevent damage but) retains regenerative capacity | NA | [ | ||
| Wistar | EAO ± | 56 days after first treatment | ketotifen reduced MC number increase | ketotifen reduced severity of histopathological testicular damage | ketotifen reduced testicular damage | NA | [ | |
|
| C57BL6/N or C57BL/6J | EAEO | 30–80 days after 1st immunisation | MC number increase in interstitium from low to high-grade EAEO | severe EAEO: ST diameter reduction, germ cell sloughing, SC-only tubules | macrophage and leukocyte number increase, fibrosis around ST | NA | [ |
|
| ||||||||
|
| Sprague–Dawley | torsion ± | 30 days after treatment | ketotifen reduced increased MC numbers—contralateral testis | ketotifen reduced germinal epithelium sloughing, ST atrophy, walls fibrosis—contralateral testis | interstitial edema | NA | [ |
| Sprague-Dawley | torsion-detorsion ± | after torsion | MC degranulation; VIP—protective effect (2 h); no MCs in interstitium | histological abnormalities; VIP reduced (2 h torsion) | histological abnormalities; VIP reduced (2 h torsion) | NA | [ | |
| Sprague-Dawley | torsion; contralateral testis analysis | 10, 30, and 80 days after torsion | maximum increase in MC number 30 days post-op | germinal epithelium sloughing (spermatocyte and spermatid apoptosis), ST atrophy, fibrosis, diameter, and Johnsen score decrease; possible reversibility | interstitial edema, T-lymphocyte, and macrophage number elevation | NA | [ | |
|
| dYY | torsion; contralateral testis analysis | 4–24 weeks after torsion | MC number increase in interstitium, maximum 8 weeks post-op | no histological changes | no histological changes | NA | [ |
|
| Wistar | 1. immobilisation cold stress 3h 3 days PND 15, 30, 45 ± | after treatment | 1. VIP reduced MC degranulation and maturation | NA | 1. VIP prevented focal LC depletion | NA | [ |
| Wistar | torsion/detorsion ± hypothermia for 30 or 90′ prior to detorsion | 8 weeks after operation | torsion/detorsion significantly increased MC number | hypothermia increased Johansen score, reduced by torsion/detorsion | hypothermia ameliorated interstitial edema | NA | [ | |
|
| ||||||||
|
| Wistar | EB on PND 1 | PND 45 and 90 | strong increase of MC number, interstitium at PND 45 | maturation arrest at the level of pachytene spermatocytes | increased proportion of interstitium (fibrosis and edema) | NA | [ |
| Wistar | 1. EB on PND 1 | PND 45 | 1. MC number increase after estrogen in the testis | 1. impaired spermatogenesis | 1. immature interstitial cells | NA | [ | |
| Wistar | EB on PND 1 | PND 15–90 | MC in interstitium on PND 17, increase in number by PND 45 and mature by PND 90 | NA | mature LC from PND 90 | NA | [ | |
| Wistar | 1. EB treatment on PND 1 | 1. PND 35–70 | 1. strong increase of MC number, interstitium at PND 35–70 testicular serotonin increase | NA | 1. LC depletion on PND 35; normal number on PND 70 | NA | [ | |
|
| ||||||||
|
| Wistar | ethanol and | 31 days after 1st treatment | decreased only the number of degranulated MCs | no effect | NA | NA | [ |
| UchB (Wistar) | ethanol 100 days | after treatment | no difference in MC number (testis); increase in total number of degranulated MCs (epidydimis) | NA | NA | NA | [ | |
| Wistar | ethanol 54 days | after treatment | no difference (testis); increase of MC number and degranulation (cauda & initial segment) | ethanol: mature spermatid number, mobile sperm count reduction; abnormal seminiferous tubule morphology | NA | NA | [ | |
|
| ||||||||
|
| WT and transgenic AROM+ | AROM+ alteration | 4-, 9-, and 15- month-old | MC number increase in interstitium and during aging | spermatogenic disruption progression during aging (GC depletion to absence at 15 months) | LC hyperplasia and hypertrophy (4 months), giant multinucleated macrophage number progression; LC adenomas (9- and 15-month-old) | NA | [ |
| Mt-hAMH and C57BL/6 | Mt-hAMH alteration | 5-month-old | abundant MC in the interstitium | lower length of ST, vacuolization of Sertoli cells, loss of GC | LC depletion | infertility after 3 rounds of consecutive pairing | [ | |
| WT (C57BL/6) and RORα-deficient | RORα-deficiency alteration | 10–12-week-old | MC in the interstitium and within the seminiferous tubule near BM | ST diameter and germinal epithelium height decrease (GC apoptosis), basal membrane irregularities, hypospermatogenesis | LC vacuolization number reduction | NA | [ | |
|
| ||||||||
|
| Wistar | 3–90 days after infection | MCs in inflammatory lesions of the epididymis 30 days after | germinal epithelium loss, spermatid giant cells after 7–70 days | interstitial fibrosis after 7–70 days | NA | [ | |
|
| 0–10 weeks after infection | MC number increase in the interstitium | ST diameter decrease (loss of GC), increase with time | LC accumulation, mononuclear cell infiltration, increase with time | NA | [ | ||
|
| ||||||||
|
| Wistar | experimental UDT (newborn) ± | after orchidectomy | experimental UDT increased, and ketotifen decreased MC number in scrotal and abdominal testis | UDT: ST diameters decreased, ST basement membranes thickened, and spermatogenesis decreased—both testes; ketotifen prevented | interstitial fibrosis; ketotifen prevented | NA | [ |
| Sprague-Dawley | PND 15–17 unilateral cryptorchidism | 15 days after treatment | MC number increase in cryptorchid (higher) and scrotal (lower) testis | ST atrophy, diameter reduction, degenerative changes, GC disconnection from BM, BM thickening, destruction in tight junctions between SCs, SCs, and spermatogenic cells, decomposition of cytoplasmic bridges between spermatogenic cells | perivascular and interstitial fibrosis, edema, congestion, hemorrhage | NA | [ | |
|
| domestic | cryptorchidism (unilateral and bilateral) | 9-month-old | abundant MCs in bilateral cryptorchid testes interstitium | NA | unilateral: fibrosis and LC degeneration in abdominal testis | NA | [ |
|
| ||||||||
|
| Sprague-Dawley | topical histamine, ritanserin, ketanserin, histamine, and substance 48/80 | 30 min after treatment | MC degranulation after histamine and substance 48/80 (dose-dependant) | NA | NA | NA | [ |
| Wistar | acyclovir i.p. 15 consecutive days (3 doses) | 18 days after last treatment | increase of MC number in the testicular interstitium and peritubular area with higher doses | ST diameter, epithelial height (cell loss), tubular differentiation index, spermiogenesis index, repopulation index (higher dose) decrease | LC atrophy, connective tissue increase | lower pregnancy rate | [ | |
| Wistar | 1. Cl2MDP-lp injection PND 5, 10, 15, 20, 25 | 1. PND 10–35 | 1. MC in interstitium 10 and 15 days after treatment | NA | 1. short-term LC depletion after treatment PND 5–15 and long term LC depletion after treatment on PND 20–25 | NA | [ | |
| Wistar | males with no mating experience and colony breeders analyzed at PND 40–170 | PND 40, 60, 90, 120 | serotonin + MC increase PND 40- 90; MC number at peak on PND 90 | NA | NA | NA | [ | |
| Sprague-Dawley | genistein ± DEHP in utero | PND 60, 120, 180 | genistein + DEHP: MC marker increase on PND 120 | genistein + DEHP: disruption in Sertoli cell function, different stage spermatogonia change | DEHP: LC number decrease PND 120 | NA | [ | |
* fertility analysis by the pairing of males after treatment. MC—mast cell, ST—seminiferous tubule, EDS—ethylene diethylstilboestrol, PNDpostnatal day, GCgerm cell, TA—tunica albuginea, LC—Leydig cell, NA—not analyzed, SC—Sertoli cell, GnRH—gonadotropin-releasing hormone, ZnO NP—zinc oxide nanoparticles, EP—ethyl pyruvate, EA(E)O—experimental autoimmune (epididymo)orchitis, PAR2—protease-activated receptor-2, VIP—vasoactive intestinal peptide, EB—estradiol benzoate, AROM—mice expressing human P450 aromatase cDNA, Mt-hAMH—AMH over-expressing mice, RORα—retinoid-related orphan nuclear receptor alpha, BM—basal membrane, UDT—unilateral descendent testis, Cl2MDP—dichloromethylene diphosphonate, hCG—human chorionic gonadotropin, hFSH—follicle-stimulating hormone DEHP—di-(2-ethylhexyl) phthalate. If not stated otherwise, adult, sexually mature animals were used. Underlined are substances that reduced or ameliorated the experimental effect on MCs.